“Ningwang” plummeted by 100 billion, the market value evaporated, and “taking medicine and drinking” reappeared. The five major institutions studied and judged the future market

On December 24, the three major A-share indexes weakened and collectively closed down. As of the closing, the Shanghai index fell 0.69%, the Shenzhen Component Index fell 1.03% and the gem index fell 2.27%; The total turnover of Shanghai and Shenzhen stock markets was 1131.8 billion yuan, and the turnover of the two markets exceeded 1 trillion yuan for the 46th consecutive trading day; With the weakening of the opening, the A-share drug and drinking market reappeared, and many traditional Chinese medicine stocks rose by the limit, Kweichow Moutai Co.Ltd(600519) closed at a new high since the second half of the year. Overall, stocks in the two cities generally fell, with more than 3400 stocks falling.

On Friday, the industry sector rose less and fell more. From the perspective of Shenwan level industries, four industries rose, with commercial trade rising first, up to 1.93%, and food and beverage, agriculture, forestry, animal husbandry and fishery all rose by more than 1%; Power equipment led the decline, reaching 4.54%.

Prepared by: Zhao Ziqiang

Chinese medicine sector led the rise

The East Money Information Co.Ltd(300059) traditional Chinese medicine sector led the increase, accounting for 4.56%. 63 stocks rose, accounting for 90%. Among them, Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) , Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) closed at the 20cm limit, and 7 stocks such as Guizhou Yibai Pharmaceutical Co.Ltd(600594) , Jinghua Pharmaceutical Group Co.Ltd(002349) , Hubei Jumpcan Pharmaceutical Co.Ltd(600566) , Guiyang Xintian Pharmaceutical Co.Ltd(002873) , Dali Pharmaceutical Co.Ltd(603963) , Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) , Kunming Longjin Pharmaceutical Co.Ltd(002750) closed at the 10cm limit.

According to the news, since this year, the number of innovative traditional Chinese medicine drugs approved by the State Food and drug administration has reached 11, which is the largest year for approving the listing of new traditional Chinese medicine drugs in recent five years. According to the drug intelligence data, as of December 16, the number of applications for registration of new traditional Chinese medicine reached 58 in 2021, an increase of 114.81% compared with 2020. The distribution of traditional Chinese medicine and new drugs in the field of disease treatment is also very rich, covering the fields of respiratory system, nervous system, digestive tract and metabolism, as well as antitumor drugs and immunomodulatory drugs.

Xiangcai Securities said that policy support is the most favorable factor for the development of the traditional Chinese medicine industry. Demand side, population aging, chronic diseases, cancer incidence rate rise, disease spectrum changes, as well as residents’ income level raise health awareness, consumption upgrading and other factors to support the demand for Chinese medicine industry healthy and stable growth. In terms of investment suggestions, (1) pay attention to the innovation of modern traditional Chinese medicine and the innovation targets of modern traditional Chinese medicine with strong R & D strength and large categories; (2) Pay attention to the advantages of brand traditional Chinese medicine, formula and raw materials, and jointly build a moat of brand traditional Chinese medicine; (3) Benefit from consumption upgrading and pay attention to the subject matter of industrial chain extension and strong brand advantage.

Open source Securities: considering policy immunity, valuation cost performance and performance certainty, recommended targets: Henan Lingrui Pharmaceutical Co.Ltd(600285) , Tasly Pharmaceutical Group Co.Ltd(600535) ; Beneficiary objects: Yunnan Baiyao Group Co.Ltd(000538) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Dong-E-E-Jiao Co.Ltd(000423) , Beijing Tongrentang Co.Ltd(600085) , Jianmin Pharmaceutical Group Co.Ltd(600976) , Zhejiang Shouxiangu Pharmaceutical Co.Ltd(603896) , China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , Furui pharmaceutical, Hubei Jumpcan Pharmaceutical Co.Ltd(600566) .

the market value of “ningwang” has evaporated by 100 billion

The biggest thing about A-Shares today is the sharp decline of Contemporary Amperex Technology Co.Limited(300750) . Contemporary Amperex Technology Co.Limited(300750) closed yesterday at 622.07 yuan, received 576.80 yuan, down 45.27 yuan, and the total market value fell 105.524 billion yuan.

Ping An Fund said, “ Contemporary Amperex Technology Co.Limited(300750) The big drop was mainly due to the widespread dissemination of official account and the discussion of the US media, which led to the market’s concern about the competition pattern of the battery and the global political and trade environment. At present, the production and manufacturing of new energy vehicles and batteries is still in an unprecedented business cycle. The competition in the new energy industry is a market-oriented behavior. The speech attacks of individual countries or the media can not change the current situation of the strong competitiveness of the head company, nor can it change the competition pattern of the industry. ”

Many fund companies believe that in addition to the impact of negative news, the imminent emergence of the world’s first large-scale mass production line of sodium ion batteries, and the market’s concern that the vehicle manufacturers can not bear the price rise of lithium carbonate + the decline of subsidies, there are also factors such as fund transaction at the end of the year, such as institutional position adjustment, absolutely cashing in the income of income funds, etc.

Liu Yan, chairman of anjue assets: “ningmao” plummeted this time. The news of the launch of sodium battery in Fuyang, Anhui Province and the discovery of lithium ore belt in Tibet are the incentives. In terms of recovery, the new energy sector has increased surprisingly this year, Contemporary Amperex Technology Co.Limited(300750) has increased by 43% this year, nearly doubled, and has increased fivefold in two years. It is very normal for the market to callback.

Cathay Pacific Fund said frankly that it will be more difficult to invest in the new energy sector in the future, and it needs to sink to the perspective of structural sub industries and even individual stocks. Investors are advised to make layout or fixed investment through excellent active equity products, and do not blindly chase high or bottom.

the market shock fell on Friday. How will it be interpreted in the future?

Qin Hong {23456} senior analyst of jinbailin consulting : Although the short-term A-share market has been adjusted, the adjustment range should not be too exaggerated, not only because the super expected information of core track stocks is expected to appear at any time, but also because the liquidity environment is still expected to weaken the selling pressure and hold up the valuation of A-shares. Therefore, in operation, it is still appropriate to strengthen the tracking of core track stocks.

Hao Xinming Fangxin wealth investment fund manager : today, the new energy high boom sector led by Contemporary Amperex Technology Co.Limited(300750) weakened, and the style turned to the consumer sector led by Maotai. The significant switching between these styles continued for more than half a year, but the trading volume has always been trillion water level index, but it can not go out of the trend. That’s why. The main reason for this situation is that the epidemic factors have caused the expectation of extreme differentiation of policy effects in different industries. The strong are stronger and the weak are weaker. Resources continue to gather in the deterministic field. This change can not form a joint force, so it is difficult to have the whole market trend. Next, the market is still affected by monetary and fiscal policies, epidemic situation and other factors. When the structural differentiation is too intense, there may be a certain return, but it still changes. While the index fluctuates, there are structural opportunities between plates. Under the general pattern of national countercyclical regulation and moderately loose liquidity, there is valuation pressure and policy support, and the shock is still the main melody of the future market.

Xia Fengguang, fund manager of private placement network : at the end of the year, the cautious attitude of the market rose. From the performance of the main indexes this week, there has been a significant decline in the gem, but the performance of the Shanghai 50 index is relatively strong. This is consistent with the rhythm of hot spot transformation throughout the year. By the end of the year, industries and individual stocks with large gains are facing strong cashing pressure. The rhythm of market rotation has shown signs of tilting towards the undervalued sector represented by big finance. In 2021, the volatility of the Shanghai Composite Index hit an all-time low. It is a year when the structural market is fully interpreted. For some industries with excessive increase, the valuation pressure will be gradually reflected during the annual report. Basically, the recovery of the policy led by broad credit will support the large financial sector. The trend of the SSE 50 and even the CSI 300 index will not be too bad in the next year, and the market of structural differentiation will continue.

Liu Yan, director of investment and trading of Honghan : in terms of index, today’s decline is a technical adjustment to the trend of the previous three consecutive days; Structurally, the largest direction of capital outflow this week comes from the upstream and downstream of new energy. The loosening of chips of high-level varieties is also one of the characteristics of the end of the adjustment. The outflow of funds is conducive to the diffusion to low-level blue chip varieties. From today’s index, the decline of blue chip weight index is significantly less than that of gem + CSI 1000 index. The end of the year is approaching. Judging from the price of treasury bond futures, there is no risk of funds. The bottom of the stock market has been confirmed. From this week to next week, the probability is a stage for bulls to re gather consensus. During this period, the varieties with stable trend and taking the lead in lifting characteristics will be the main line in the future.

Liu Yan, chairman of anjue assets : a little bad performance on the news side, coupled with the global entry into the Christmas holiday, and the interaction between the capital side and the news side, finally led to today’s one-sided decline. However, the logic of the new energy track will not collapse because of the two news. On the contrary, this trampling irrational behavior will create buying opportunities for rational investors, which is worthy of careful study and judgment by investors.

(voice of Securities Daily)

 

- Advertisment -